Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Parliament's Defence Committee says there is "clear evidence of collusion" between Huawei and the Chinese state in a new report on 5G security.
"The decision to embed a technology that compromises this would constitute a gross dereliction of these duties," Mr Ellwood added, before stating: "The West must urgently unite to advance a counterweight to China's tech dominance."
It cites claims which have previously been made about Huawei's ownership model and receipt of state subsidies, but does not include new evidence.
In response a Huawei spokesperson said: "This report lacks credibility, as it is built on opinion rather than fact.
"We're sure people will see through these accusations of collusion and remember instead what Huawei has delivered for Britain over the past 20 years," they added.
Huawei: The company and the security risks explained
Huawei: The company and the security risks explained
Tobias Ellwood MP, the chair of the defence committee, unveiled the report stating: "Protecting the public and preserving our nation's security are amongst the principle responsibilities of government.
Among the committee's recommendations are proposals to form "a D10 alliance of democracies to provide alternatives to Chinese technology".
China says UK has 'poisoned' relations and will 'pay the price' if it shuns Beijing
The committee also warned that current regulations were "porous" and that "legislation lacks teeth, continuing to allow telecoms companies to prioritise profit over the public and the nation's security".
It described as "imperative" the enacting of the Telecoms Security Bill, which will make the prohibition on purchasing new Huawei equipment from the end of this year a legal obligation.
Huawei's networking kit is set to be banned by the end of this year
The report follows the government ordering that all Huawei equipment must be stripped out of the UK's telecommunication networks by 2027, as a result of US trade restrictions.
Mobile network operators will also be banned from purchasing new Huawei equipment by the end of this year. This ban impacts networking equipment and not consumer devices such as Huawei's phones and laptops.
During the witness hearings for the committee's inquiry, the culture secretary said that the government was aware "large private companies in China often have links to the Chinese Communist Party, and this was one of the factors that led to Huawei being designated as a high-risk vendor".
Guidance issued by the UK's National Cyber Security Centre states that Huawei "has always been considered higher risk by by the UK government". Reasons include China's National Intelligence Law which could compel the company's employees to "act in a way that is harmful to the UK".
New American restrictions on Huawei will prohibit US firms from providing computer chips to the company.
Clear evidence of collusion' between Huawei and Beijing, claim MPs
http://news.sky.com/story/clear-evidence-of-collusion-between-huawei-and-beijing-claim-mps-12098353
I would think most invested here will not be looking to sell a single share until after the sale completes! I can’t see the price dropping much of at all! To the contrary, I expect it to rise instantly in the morning??
I’m in and will continue to grow my investment here. I see huge growth potential now that we have the BT 5G contract.
Following on from Colins presentation I can say with great confidence that the only way is upwards and onwards for ODX!
I would love Vlad to come pick me up in his helicopter and take me for a round of golf and a few beers!
Source : https://apple.news/AOrQzRj4JSNKicF9MwSH3pg
Eli Lilly and Co.’s experimental antibody treatment for Covid-19 reduced the rate at which symptomatic patients were hospitalized compared to a placebo, according to preliminary study results released by the company and its partner.
Indianapolis-based Lilly and AbCellera Biologics Inc., a closely held Canadian biotechnology company, are co-developing neutralizing antibodies derived from one of the earliest patients in the U.S. to contract Covid-19. They are among a handful of companies, including Regeneron Pharmaceuticals Inc., AstraZeneca Plc., GlaxoSmithKline Plc and its partner Vir Biotechnology Inc. pursuing antibody therapies to combat the pandemic.
Interim results from a mid-stage trial that evaluated multiple dosages found that Lilly and AbCellera’s treatment, known as LY-Cov555, was associated with a 1.7% rate in hospitalizations and ER visits among those who took the treatment compared with a 6% rate among people on a placebo, a 72% reduction in risk. No patients in the study progressed to mechanical ventilation or died.
Lilly’s shares rose 0.9% to $151.48 at 10:29 a.m. in New York trading on Wednesday. The lack of a response at the highest dose and scant detail on the lower hospitalization rates drew Wall Street analyst scrutiny.
The results were “odd” Bloomberg Intelligence’s Sam Fazeli wrote in a note, adding “It’s not clear which dose drove the 72% reduction in hospitalizations. Very few patients were hospitalized, raising a risk that the effect is by chance. We need to see more data.”
The early results also showed that one of three doses of the antibody drug tested against Covid-19 lowered the amount of virus present 11 days after patients received the treatment compared to the placebo. A 2,800 milligram dose version of the drug reduced the viral load, though the 700 mg and 7,000 mg doses did not achieve that end point. Most patients, including those receiving the placebo, demonstrated near complete viral clearance by the eleventh day.
Lilly said it will soon publish the results of this interim analysis in a peer-reviewed journal and discuss appropriate next steps with regulators.
Regeneron is expected to report results of its own at the end of this month. Jefferies analyst Biren Amin was confident the biotech company’s antibody ****tail approach could prove more effective than Lilly’s, which relies on a single antibody..
Warp Speed
On Tuesday, top officials at Operation Warp Speed, the Trump administration’s effort to expedite the development of an inoculation and treatment, identified antibody therapies as one of its foremost R&D priorities to counter Covid.
Moncef Slaoui, who is leading the Trump Administration’s Warp Speed initiative, wrote in The New England Journal of Medicine that the U.S. government plans to support manufacturing of the “most potent” monoclonal antibody products “so that hundreds of thousands of doses could be deployed this fall and winter.”
06:35 ODX summary. £1.05 by end of week to £1.80 in next 1-2 months.
https://www.pscp.tv/w/cjBhtHR3LTEyNjA0MDY5OTU1MjM0NTcwMjR8MVBsSlFOeVBsT254RYos1S8XrwGWBb5YTwAMc5p9drlKuHX-R2W3i8SCkqU6?t=1m53s
Lithium is a game changer! Chinese won’t be mining for nothing! They will be digging deep for Lithium!
I’m willing to take my chances and am always the optimist! Your either in or your out. There’s no middle ground here.
Short off elsewhere! The interview and statements shared by the CEO give me a high degree of confidence in KOD. Happy to be invested! Chinese will help harvest our Lithium and deliver to the Global demand!
Interview with Bernard posted on Twitter by sharetalk. Worth a listen!
https://audioboom.com/posts/7677346-bernard-aylward-ceo-of-kodal-minerals-plc-kod-l-podcast
Below statements are from @Kodalminerals twitter handle posted 8th Sept 2020.
Lithium has been added to the EU's 2020 CRM list for the first time due to its importance in green tech. The supply of CRMs to the EU is highly concentrated & will require up to 18x more lithium by 2030 to meet demand - creating a supply gap for $KOD's Bougouni Project to resolve.
The European Commission has released a document on the critical role raw materials play in creating a more secure & sustainable future. These materials play a crucial role in Europe's goal to deliver the Green Deal through a new industrial strategy.
Top up on the lows. Good luck all!
I would say it’s the perfect opportunity to top up before this breaks through the 15p barrier once again on no news! Once news comes this will be into new highs altogether!
The drop today will be short lived and has presented a perfect opportunity to top up. Those holding will reap the rewards. A little patience doesn’t go astray when your a shareholder! It’s only a matter of time before the news breaks and Hemo is heading into £1+ territory. JMO GLA